TGF-β Pathway Inhibition Protects the Diaphragm From Sepsis-Induced Wasting and Weakness in Rat.
Journal
Shock (Augusta, Ga.)
ISSN: 1540-0514
Titre abrégé: Shock
Pays: United States
ID NLM: 9421564
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
entrez:
16
5
2020
pubmed:
16
5
2020
medline:
2
6
2021
Statut:
ppublish
Résumé
Sepsis is a frequent complication in patients in intensive care units (ICU). Diaphragm weakness, one of the most common symptoms observed, can lead to weaning problems during mechanical ventilation. Over the last couple of years, members of the transforming growth factor (TGF) β family, such as myostatin, activin A, and TGF-β1, have been reported to strongly trigger the activation of protein breakdown involved in muscle wasting. The aim of this study was to investigate the effect of TGF-β inhibitor LY364947 on the diaphragm during chronic sepsis.Rats were separated into four groups exposed to different experimental conditions: Control group, Septic group, Septic group with inhibitor from day 0 (LY D0), and Septic group with inhibitor from day 1 (LY D1). Sepsis was induced in rats by cecal ligation and puncture, and carried out for 7 days.Chronic sepsis was responsible for a decrease in body weight, food intake and diaphragm's mass. The inhibitor was able to abolish diaphragm wasting only in the LY D1 group. Similarly, LY364947 had a beneficial effect on the diaphragm contraction only for the LY D1 group. SMAD3 was over-expressed and phosphorylated within rats in the Septic group; however, this effect was reversed by LY364947. Calpain-1 and -2 as well as MAFbx were over-expressed within individuals in the Septic group. Yet, calpain-1 and MAFbx expressions were decreased by LY364947.With this work, we demonstrate for the first time that the inhibition of TGF-β pathway during chronic sepsis protects the diaphragm from wasting and weakness as early as one day post infection. This could lead to more efficient treatment and care for septic patients in ICU.
Identifiants
pubmed: 32413000
doi: 10.1097/SHK.0000000000001393
pii: 00024382-202006000-00015
doi:
Substances chimiques
Transforming Growth Factor beta
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
772-778Références
Friedrich O, Reid MB, Van den Berghe G, Vanhorebeek I, Hermans G, Rich MM, Larsson L. The sick and the weak: neuropathies/myopathies in the critically ill. Physiol Rev 95 (3):1025–1109, 2015.
Griffiths RD, Hall JB. Intensive care unit-acquired weakness. Crit Care Med 38 (3):779–787, 2010.
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche J-D, Coopersmith CM, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315 (8):801–810, 2016.
Gueret G, Guillouet M, Vermeersch V, Guillard E, Talarmin H, Nguyen B-V, Rannou F, Giroux-Metges MA, Pennec JP, Ozier Y. [ICU acquired neuromyopathy]. Ann Fr Anesthèsie Rèanimation 32 (9):580–591, 2013.
Vincent J-L, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302 (21):2323–2329, 2009.
Lang CH, Frost RA, Vary TC. Regulation of muscle protein synthesis during sepsis and inflammation. Am J Physiol Endocrinol Metab 293 (2):E453–459, 2007.
Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. Lancet Neurol 10 (10):931–941, 2011.
McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387 (6628):83–90, 1997.
Lach-Trifilieff E, Minetti GC, Sheppard K, Ibebunjo C, Feige JN, Hartmann S, Brachat S, Rivet H, Koelbing C, Morvan F, et al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol 34 (4):606–618, 2014.
Smith IJ, Aversa Z, Alamdari N, Petkova V, Hasselgren P-O. Sepsis downregulates myostatin mRNA levels without altering myostatin protein levels in skeletal muscle. J Cell Biochem 111 (4):1059–1073, 2010.
orel J, Palao J-C, Castells J, Desgeorges M, Busso T, Molliex S, Jahnke V, Del Carmine P, Gondin J, Arnould D, et al. Regulation of Akt-mTOR, ubiquitin-proteasome and autophagy-lysosome pathways in locomotor and respiratory muscles during experimental sepsis in mice. Sci Rep 7 (1):10866, 2017.
ill NE, Saeed S, Phadke R, Ellis MJ, Chambers D, Wilson DR, Castells J, Morel J, Freysennet DG, Brett SJ, et al. Detailed characterization of a long-term rodent model of critical illness and recovery. Crit Care Med 43 (3):e84–96, 2015.
Rebbapragada A, Benchabane H, Wrana JL, Celeste AJ, Attisano L. Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol Cell Biol 23 (20):7230–7242, 2033.
Ohsawa Y, Okada T, Nishimatsu S-I, Ishizaki M, Suga T, Fujino M, Murakami T, Uchino M, Tsuchida K, Noji S, et al. An inhibitor of transforming growth factor beta type I receptor ameliorates muscle atrophy in a mouse model of caveolin 3-deficient muscular dystrophy. Lab Invest 92 (8):1100–1114, 2012.
Rossignol B, Gueret G, Pennec J-P, Morel J, Rannou F, Giroux-Metges M-A, Talarmin H, Gioux M, Arvieux CC. Effects of chronic sepsis on contractile properties of fast twitch muscle in an experimental model of critical illness neuromyopathy in the rat. Crit Care Med 36 (6):1855–1863, 2008.
Crowell KT, Kelleher SL, Soybel DI, Lang CH. Marginal dietary zinc deprivation augments sepsis-induced alterations in skeletal muscle TNF-α but not protein synthesis. Physiol Rep 4 (21):e13017, 2016.
Minnaard R, Drost MR, Wagenmakers AJM, van Kranenburg GP, Kuipers H, Hesselink MKC. Skeletal Muscle wasting and contractile performance in septic rats. Muscle Nerve 31 (3):339–348, 2005.
Demoule A, Jung B, Prodanovic H, Molinari N, Chanques G, Coirault C, Matecki S, Duguet A, Similowski T, Jaber S. Diaphragm dysfunction on admission to the intensive care unit. Prevalence, risk factors, and prognostic impact: a prospective study. Am J Respir Crit Care Med 88 (2):213–219, 2013.
Zhang H-X, Du J-M, Ding Z-N, Zhu X-Y, Jiang L, Liu Y-J. Hydrogen sulfide prevents diaphragm weakness in cecal ligation puncture-induced sepsis by preservation of mitochondrial function. Am J Transl Res 9 (7):3270–3281, 2017.
Supinski GS, Wang L, Song X-H, Moylan JS, Callahan LA. Muscle-specific calpastatin overexpression prevents diaphragm weakness in cecal ligation puncture-induced sepsis. J Appl Physiol (1985) 117 (8):921–929, 2014.
Supinski GS, Alimov AP, Wang L, Song X-H, Callahan LA. Calcium-dependent phospholipase A2 modulates infection-induced diaphragm dysfunction. Am J Physiol Lung Cell Mol Physiol 10 (10):L975–984, 2016.
Supinski GS, Vanags J, Callahan LA. Eicosapentaenoic acid preserves diaphragm force generation following endotoxin administration. Crit Care 14 (2):R35, 2010.
Fischer DR, Sun X, Williams AB, Gang G, Pritts TA, James JH, Molloy M, Fischer JE, Paul RJ, Hasselgren PO. Dantrolene reduces serum TNFalpha and corticosterone levels and muscle calcium, calpain gene expression, and protein breakdown in septic rats. Shock 15 (3):200–207, 2013.
Guillard E, Gueret G, Guillouet M, Vermeersch V, Rannou F, Giroux-Metges M-A, Pennec J-P. Alteration of muscle membrane excitability in sepsis: possible involvement of ciliary nervous trophic factor (CNTF). Cytokine 63 (1):52–57, 2013.
Schumer W, Erve PR, Obernolte RP. Endotoxemic effect on cardiac and skeletal muscle mitochondria. Surg Gynecol Obstet 133 (3):433–436, 1971.
Guillouet M, Gueret G, Rannou F, Giroux-Metges M-A, Gioux M, Arvieux CC, Pennec J-P. Tumor necrosis factor-α downregulates sodium current in skeletal muscle by protein kinase C activation: involvement in critical illness polyneuromyopathy. Am J Physiol Cell Physiol 301 (5):C1057–1063, 2011.
Han HQ, Zhou X, Mitch WE, Goldberg AL. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol 45 (10):2333–2347, 2013.
Jones KL, Mansell A, Patella S, Scott BJ, Hedger MP, de Kretser DM, Phillips DJ. Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc Natl Acad Sci U S A 104 (41):16239–16244, 2007.
Imai K, Takeshita A, Hanazawa S. Transforming growth factor-beta inhibits lipopolysaccharide-stimulated expression of inflammatory cytokines in mouse macrophages through downregulation of activation protein 1 and CD14 receptor expression. Infect Immun 68 (5):2418–2423, 2000.
Brosh N, Sternberg D, Honigwachs-Sha’anani J, Lee B-C, Shav-Tal Y, Tzehoval E, Shulman LM, Toledo J, Hacham Y, Carmi P, et al. The plasmacytoma growth inhibitor restrictin-P is an antagonist of interleukin 6 and interleukin 11. Identification as a stroma-derived activin A. J Biol Chem 270 (49):29594–29600, 1995.
Marie C, Cavaillon JM, Losser MR. Elevated levels of circulating transforming growth factor-beta 1 in patients with the sepsis syndrome. Ann Intern Med 125 (6):520–521, 1996.
Lee J-K, Choi SM, Lee J, Park YS, Lee CH, Yim J-J, Yoo C-G, Kim YW, Han SK, Lee S-M. Serum activin-A as a predictive and prognostic marker in critically ill patients with sepsis. Respirology 21 (5):891–897, 2016.